Top 10 Tasimelteon (Hetlioz) Generic Manufacturers in China
The global pharmaceutical market continues to expand, with the generics segment playing a pivotal role in driving accessibility and affordability of medications. As of 2023, the global generic drugs market is valued at approximately USD 400 billion and is expected to grow at a CAGR of 6.3% through 2030. In China, the production of generic pharmaceuticals has surged, making the country one of the leading players in the global market. Notably, Tasimelteon (Hetlioz), a medication approved for the treatment of Non-24-Hour Sleep-Wake Disorder, has seen a rise in generic competition, particularly from Chinese manufacturers. Below is a list of the top 10 Tasimelteon generic manufacturers in China.
1. Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co. is a prominent player in the generic drug market, specializing in various therapeutic areas, including oncology and neurology. The company reported a revenue of approximately USD 1.1 billion in 2022 and has a significant share in the Tasimelteon market, focusing on high-quality production standards.
2. Suzhou Tianlu Pharmaceutical Co., Ltd.
Suzhou Tianlu is known for its innovative approach in the production of generic drugs. The company produces around 30 tons of active pharmaceutical ingredients (APIs) per year and has been expanding its portfolio to include Tasimelteon, which shows a growing market share within the CNS therapeutic area.
3. Hunan Er-Kang Pharmaceutical Co., Ltd.
Hunan Er-Kang specializes in the development and manufacturing of generics and has a production capacity of over 50 million tablets annually. They have successfully entered the Tasimelteon market, contributing to the competitive landscape with cost-effective alternatives.
4. Jiangsu Hengrui Medicine Co., Ltd.
As one of the largest pharmaceutical companies in China, Jiangsu Hengrui has a strong focus on research and development. Their annual revenue exceeded USD 3.3 billion in 2022, and they have been investing heavily in expanding their generic offerings, including Tasimelteon.
5. Shanghai Pharmaceutical Holding Co., Ltd.
Shanghai Pharmaceutical operates in various segments of the pharmaceutical industry, with a reported annual revenue of USD 1.5 billion. The company is expanding its generic portfolio, including Tasimelteon, to meet the growing demand for affordable medication.
6. Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group is a significant player in the generic pharmaceuticals market, producing over 100 million units of various medications annually. Their entry into the Tasimelteon market has been marked by strong production capabilities and partnerships for distribution.
7. Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun is known for its extensive range of generic drugs and APIs, with a reported revenue of approximately USD 1.2 billion. The company has made strides in the Tasimelteon market by leveraging its established manufacturing facilities and quality control processes.
8. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan, with a revenue of USD 2.1 billion, is a leading manufacturer of pharmaceutical products in China. The company is committed to expanding its generic drug portfolio, including Tasimelteon, to serve both domestic and international markets.
9. Shenzhen Salubris Pharmaceuticals Co., Ltd.
Shenzhen Salubris has a robust focus on generic drugs and biopharmaceuticals, with a production capacity of over 1 billion tablets annually. Their investment in Tasimelteon production aligns with their strategy to meet growing global demands for generics.
10. Jilin Chemical Industry Group Co., Ltd.
Jilin Chemical Industry Group is emerging as a formidable force in the generic pharmaceuticals sector, producing a wide range of APIs, including those for Tasimelteon. With a reported production volume of approximately 20 tons annually, they are expanding their influence in the market.
Insights
The generics market for Tasimelteon in China is poised for significant growth, driven by rising healthcare costs and an increasing emphasis on affordable medication options. With a projected growth rate of 7% in the generic pharmaceuticals sector, manufacturers are ramping up production capabilities and enhancing quality control measures. China’s role as a leading supplier of generic drugs is underscored by its growing export capabilities, which reached USD 30 billion in 2022. The competitive landscape is characterized by consolidation and partnerships among manufacturers to optimize supply chains and broaden market reach. As the demand for Tasimelteon continues to rise, manufacturers are likely to increase their investment in research and development to enhance product offerings and meet regulatory requirements.
Related Analysis: View Previous Industry Report
